Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 6/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 10/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611913 | 0.81 | DAGLA (0.41) | FAAHCES1DAGLAXDHNLRP3 | |
| SCHEMBL3613201 | 0.77 | FAAH (0.36) | FAAHCES1DAGLAXDHNLRP3 | |
| SCHEMBL3620435 | 0.74 | FAAH (0.39) | FAAHCES1DAGLACTSSCYP3A4 | |
| SCHEMBL3623532 | 0.73 | CTSS (0.41) | FAAHCES1DAGLACTSSCYP3A4 | |
| SCHEMBL3623528 | 0.71 | CTSS (0.41) | FAAHCES1DAGLACTSSCYP3A4 | |
| SCHEMBL3622455 | 0.65 | FAAH (0.35) | FAAHCES1DAGLACTSS | |
| SCHEMBL3611917 | 0.64 | FAAH (0.38) | FAAHCES1DAGLACTSSCYP3A4 | |
| SCHEMBL3962620 | 0.61 | FAAH (0.85) | FAAHCES1DAGLA | |
| SCHEMBL4051507 | 0.60 | DAGLA (0.67) | FAAHCES1DAGLAXDH | |
| SCHEMBL5672032 | 0.60 | DAGLA (0.67) | FAAHCES1DAGLAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1761485-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | FAAH 341/4885CES1 156/4885DAGLA 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.